Dow Jones 10544.51 +30.62 11:06 am PST, July 13, 2005  NASDAQ 2142.45 -0.70 For info, visit access.smallcapnetwork.com S & P 500 1222.25 +0.04 Change your subscription status here Russell 2000 668.30 -2.49 VOLUME 05: ISSUE 53  Feature: BioCurex Awakens. Tracking Eden's Volatility. Eden Energy (OTCBB: EDNE) shares have, to say the least, had an active few days. After running up to $4.59 on Monday from under $3 last week, the shares pulled back to just under $4 Tuesday and closed the day at $4.24. Whether the rise is a result of new investor interest, short covering or a combination of both, the action simply means that the shares have decisively popped up on significantly more radar screens. That's a good thing. Since the 30th of June, the daily share volume has ranged from 800,000 to over 3 million. We first Alerted the readership to Eden at $2.80 with subsequent accumulation suggestions from $2.50 to $3. The shares were trading at around $4.05-$4.10 at the opening, Wednesday. That's roughly a 45 percent gain in a scant few weeks. While we are cautious short-term about being aggressive buyers over $4, some exposure is certainly warranted given Eden's exploration potential, which we have frequently noted here and on the SCBLOG. We would like to see the shares retrace to the .382 or .618 levels as noted on the chart prior to initiating any large new buying--maybe pick up shares at one and more if it gets to the lower end of the retracement range.  At the time of writing this tome, the shares had pulled back to just under $3.80 or within a few cents of that first technical retracement level. Picking up a few shares for risk-oriented investors at these levels might well make sense. That said, for traders, the volatility of this stock has to be extremely compelling. For long-term investors, any new buying should be done on dips. While we are all in favor of rising share prices, sometimes a breather is the best thing that could happen. Some consolidation would serve the technical picture well at this point. As we have also frequently noted, activity in the Great Basin area--either real or rumored --is bound to affect the Eden share price. Vigilance and strategic trading will likely be the watchwords as the company ramps up to its drilling program at its Noah property in the fall. We continue to feel that the potential for Eden is enormous. The shares will likely remain volatile allowing those investors who like this type of action excellent opportunities to trade the shares. A core holding, especially of lower priced shares, should be held to take advantage of news from and activity in the Great Basin area. Remember, Eden is virtually the only public company with exposure in the area and the Noah target is, so far, the biggest and potentially the best play there.   BioCurex Awakens, Gets Peer-Reviewed and More... Even though there has not been a great deal of recent news from this biotech, BioCurex (BOCX.PK) saw renewed interest Tuesday as a result of some exposure through an Internet based newsletter. The shares popped to $1.43, Tuesday on decent volume and subsequently settled to close at $1.17. The shares opened Wednesday at $1.20. In the release below, the company announced some quality publications that have written pieces regarding its technology. Links to the articles are at BioCurex's website (www.biocurex.com) for readers to access. The life-blood of small biotechs is recognition in peer-reviewed journals and other like-oriented publications. The inclusion exposes the technology to significantly more potential R&D partners and licensees. BOCX traded to the .382 retracement of the down move it's had for a while, which was no surprise. However, if it can close above that .382 resistance, the next stop may very well be the .618 level. Of course if it breaks above that, it will most likely want to test the old high. The shares have been stuck in a range of 95 cents to $1.05 seemingly forever and, while yesterday's action may not be the ultimate catalyst to break that trend, it definitely brought in more investors to the story and that's also always a good thing.  The recent action evidences one thing for sure; new investors can obviously get just as excited as the rest of us once exposed to the company and it's potential. While we are not aware of any solid timeline for the company to regain a more senior market listing, it is certainly foremost on the agenda. Again as we have oft stated, that eventuality will return the shares to more and larger radar screens. Volumes have been creeping up of late, which is also a very positive sign. More news, more exposure should send it on its way, hopefully soon. That said, even on the pinks, the potential for the company, in our view, remains amazing and feel that the shares continue to be undervalued when measured against that potential. With the prolonged share price consolidation at or around the $1 level, it appears a floor or strong support level has been established and we continue to suggest that risk oriented long-term investors accumulate shares.   PRESS RELEASE Press Release Source: BioCurex, Inc. Peer Reviewed Journal Publishes RECAF Results. RICHMOND, British Columbia, July 13, 2005, -- BioCurex Inc. (BOCX.PK - News) announced today the publication of its tissue and serum RECAF results in the last issue (June) of the journal IVD Technology (IVD is an acronym for In-Vitro Diagnostics, meaning clinical studies done on samples in a test tube). The article was initially requested by IVDT in 2003 and it was originally limited to the detection of cancer cells on tissue sections. Publication was then postponed in order to include the results obtained on serum samples. The article's title is "A new broad-spectrum cancer marker". IVDT has a circulation of 15,000 mostly among professional personnel in product R&D, design, manufacturing, quality assurance, regulatory affairs, and corporate management. All manuscripts are subjected to double-blind peer review to ensure the quality and relevance of the materials. The publisher disallows promotion of brands, products or services offered by authors.  In addition to the IVDT article, Hematology Oncology News & Issues interviewed Dr. Moro (BioCurex's CEO) and as a result it published, in its May 2005 issue, a commentary on RECAF entitled: "RECAF biomarker for common cancers provides patient, doctor benefits".  An excerpt of the article reads:"RECAF technology has the potential to benefit patients, doctors and the health care system by ruling out unnecessary and sometimes painful, biopsies; allowing oncologists to react promptly to elevated RECAF presence; and diagnosis patients at earlier stages." Hematology Oncology News & Issues is a NEWS magazine. Its charter is to report on the latest developments in these medical specialties and provide a forum for the exchange of ideas among the professional disciplines responsible for delivering care to the cancer patient. Also, the May issue of "View on Biotechnology" , a supporting publication to Pharmavoice, which reaches 17,000 US based life-sciences executives, dedicated its May issue to: "Thought Leader Perspective. An overview of the biotechnology industry". Dr. Moro was one of the 16 "thought leaders" interviewed. None of the publications was paid for space, nor does BioCurex advertise in any of them. Links to the abovementioned publications can be found in the News section of our web site (www.biocurex.com). Dr. Moro, President & CEO of BioCurex stated: "In the current business environment it is necessary but not sufficient to have an excellent technology; success ultimately depends on people - from the general public to industry leaders - learning about it. We are very glad to see the blood and tissue test results published in a peer reviewed publication that reaches not only scientists but also industry leaders. We are well aware of the importance of communicating our results and achievements in many different forums including journals, congresses and industry magazines. These publications, together with the invitations we have received to discuss our results in the upcoming ISOBM congress suggest that people in our field are starting to take notice of our achievements. We shall continue our efforts in that direction." About BioCurex: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To read more about the Company, please visit the News section in our web site (www.biocurex.com). Note:  The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.   Contact: Ricardo Moro BioCurex, Inc. Tel: (604) 207 9150   We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130 Subscribe Information is power and timely information is profitable. Become informed and profit from SmallCapDigest Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the SmallCapDigest Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the SmallCapDigest Member List. Receiving the SmallCapDigest Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the SmallCapDigest recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the SmallCapDigest, simply follow the instructions located at the bottom of every SmallCapDigest Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a licensed investment professional or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Visit Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 by the company for coverage of Eden Energy. TGR Group LLC has also been granted 100,000 options, exercisable at $.50 into free trading shares of Eden Energy, by Mokandi International. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. Under SEC Rule 144, 570,000 shares of the 1 million newly issued restricted shares are now eligible for sale into the public market. TGR Group has submitted the approriate filings to sell the shares.  In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. From time to time TGR Group LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. The editor, members of the editor's family, and/or entities with  which the editor is affiliated aside from TGR Group LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain statements that appear forward as it relates to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.